Login to Your Account

China's Yisheng moves forward with rabies vaccine in U.S.

By Pearl Liu
Staff Writer

Wednesday, January 11, 2017

HONG KONG – Beijing-based Yisheng Biopharma Co. Ltd. said the recent U.S. FDA orphan designation for its PIKA rabies orphan drug is another milestone in its push to expand outside of China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription